Daniel M Skovronsky
Overview
Explore the profile of Daniel M Skovronsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
5992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J, et al.
JAMA
. 2023 Jul;
330(6):512-527.
PMID: 37459141
Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, And Participants:...
2.
Dougan M, Azizad M, Mocherla B, Gottlieb R, Chen P, Hebert C, et al.
Clin Infect Dis
. 2021 Oct;
75(1):e440-e449.
PMID: 34718468
Background: Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods: This...
3.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb R, Chen P, et al.
N Engl J Med
. 2021 Jul;
385(15):1382-1392.
PMID: 34260849
Background: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and...
4.
Cohen M, Nirula A, Mulligan M, Novak R, Marovich M, Yen C, et al.
JAMA
. 2021 Jun;
326(1):46-55.
PMID: 34081073
Importance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against...
5.
Mintun M, Lo A, Evans C, Wessels A, Ardayfio P, Andersen S, et al.
N Engl J Med
. 2021 Mar;
384(18):1691-1704.
PMID: 33720637
Background: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment...
6.
Gottlieb R, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al.
JAMA
. 2021 Jan;
325(7):632-644.
PMID: 33475701
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with...
7.
Nirula A, Shen L, Skovronsky D
N Engl J Med
. 2020 Dec;
384(2):189.
PMID: 33378611
No abstract available.
8.
Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J, et al.
N Engl J Med
. 2020 Oct;
384(3):229-237.
PMID: 33113295
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to...
9.
Hefti F, Kung H, Kilbourn M, Carpenter A, Clark C, Skovronsky D
PET Clin
. 2016 May;
5(1):75-82.
PMID: 27157484
The early detection and monitoring of neurodegenerative diseases, including Parkinson disease, Alzheimer disease, dementia with Lewy bodies and other dementias, and movement disorders, represent a significant unmet medical need. Tools...
10.
Grundman M, Johnson K, Lu M, Siderowf A, Dellagnello G, Arora A, et al.
Dement Geriatr Cogn Disord
. 2016 Jan;
41(1-2):80-92.
PMID: 26745445
Background: Published appropriate use criteria (AUC) describe patients for whom amyloid positron emission tomography (PET) might be most useful. This study compared the impact of amyloid PET on diagnosis and...